Address: Vijzelmolenlaan 9, 3447 GX, Woerden,Netherlands
Tel: +31 348574222
Web: http://www.b-ms.nl/
The headquarters of Bristol-Myers Squibb (B-MS) Netherlands several divisions are located in Woerden.
B-MS is originally an American company and has offices worldwide. B-MS has operated for over 40 years In the Netherlands and is a leader in innovative medicines and health products.
For more information about B-MS International, visit: http://www.bms.com/
Squibb settled in 1967 in The Hague. Bristol-Myers since 1971 in the Netherlands. In 1989 both companies merged and Woerden was chosen as a location for BMS.
B-MS has 35,000 employees worldwide, of which 110 work in the Netherlands.
Global B-MS had 2008 sales of $ 20.6 billion.
In 2008, $ 3.6 billion invested in the development of new drugs (17.4% of revenue in 2007 was 17.0%).
B-MS is represented in the associations Nefarma, Netherlands Association of Innovative Drugs and AmCham, American Chamber of Commerce. Both are active in the field of advocacy for the innovative pharmaceutical industry. Topics include: authorization and reimbursement of new drugs, the funding of medicines and promote a favorable climate for innovation in the Netherlands. For more information about the industry, visit: http://www.nefarma.nl or http://www.amchampc.org
The mission of our company is focused on the life of man to the length and quality of life by developing innovative medicines and health products. The research of B-MS is focused on disease areas where there is a medical need, such as cancer, HIV / AIDS, diabetes, rheumatism, hepatitis, schizophrenia, heart disease and obesity.
Paul Korte, General Manager for Janssen in the Netherlands, highlights the strategic move and leadership position taken up by Janssen in the oncology field, and calls on Dutch healthcare stakeholders…
In an exclusive interview, the Vice President of Philips Research explains the key to continuous evolution, improving healthcare stakeholder relations, and fostering “Open Innovation.” You have been Vice President of…
Healthcare is moving towards an increased level of personalization and active participation of the patient in the decision-making process. Roland van Esch, General Manager of Zimmer Biomet Netherlands, shares his…
Teva Benelux and Nordics’ GM lifts the lid on how the company has grown to become the market leader in the Netherlands. Looking at Teva’s activities, your market leader position in…
Takeda’s goal is to become a trusted and reliable partner in the healthcare system by better understanding patients’ needs. Aarnoud Overkamp, general manager of the Dutch subsidiary, shares his perspective…
In many aspects, 2016 truly marks the dawn of a new era for Toshiba Medical Systems. Lo Wuite (LW), General Manager Managed Equipment Services (MES) Europe, and Dick Blesing (DB),…
DHL Supply Chain Benelux understands the challenges life sciences companies face and has developed solutions to help overcome them. The Vice President and Commercial Director discuss how the services of…
Yvonne van Rooy, president of the NVZ, explains the patient’s increasing role as a partner in Dutch healthcare and how greater investment in ICT is needed for the patient to fulfill this role. She further discusses…
After having successfully acquired its first dialysis center in the Netherlands, Fresenius Medical Care, the market leader for kidney failure products and services, is looking to develop more partnerships with…
Ad Schuurman of the National Health Care Institute of the Netherlands (“Zorginstituut”) explains the main missions and mandates of this organization with regards to the basic insurance package covering all Dutch citizens,…
Kees Smaling, Managing Director of Siemens Healthcare, which recently completed its first Dutch (and European) hospital financing, explains the strategic thinking that sustains Siemens’ shift to become a more comprehensive…
DB Schenker’s Bart Coenen (BC) and Vincent Coolen (VC) explain the company’s Vision 2020 and talk about the benefits for pharma companies of outsourcing their supply chain. In 2013, DB…
See our Cookie Privacy Policy Here
